ALNY
Alnylam Pharmaceuticals Inc
224.40$
+0.2%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | -66.7% | -210.2% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -108.0% | – | |
| – | +2,227.8% | +191.6% | +27.6% | +22.3% | +7.0% | +40.3% | +4.6% | -17.5% | +3.7% | +76.3% | +13.2% | +16.6% | +59.7% | -20.6% | -11.7% | -51.9% | +744.9% | +36.9% | +20.5% | -50.4% | +21.6% | +4.8% | -1.8% | |
| – | – | – | – | – | +74.3% | +24.6% | +11.9% | -4.1% | -13.1% | -26.4% | +67.5% | +59.7% | +38.5% | +65.0% | +22.9% | +70.0% | +10.8% | -20.0% | +18.5% | +39.2% | -3.9% | +22.7% | +28.0% | |
| – | – | – | – | – | – | -25.3% | – | – | -18.6% | -139.5% | – | -131.5% | – | +54.4% | +35.2% | +90.8% | +8.4% | -22.4% | +42.6% | +37.7% | – | – | – | |
| – | +9.7% | +19.8% | +381.2% | -115.8% | – | -74.9% | -178.9% | – | – | – | – | – | – | -51.0% | -116.9% | – | +792.2% | -103.2% | – | – | – | -2,089.8% | – | |
| – | +455.0% | +188.7% | -78.4% | +156.1% | +56.2% | +38.2% | -54.0% | -4.4% | -72.7% | +546.6% | -52.0% | +123.7% | +44.5% | +398.5% | +61.4% | +21.8% | +10.5% | -49.8% | +8.5% | -5.6% | -13.7% | -44.9% | +71.2% | |
| – | +476.5% | +967.7% | +16.8% | -25.7% | +823.3% | – | -19.5% | +23.6% | +359.5% | -95.9% | -3,968.0% | +320.5% | -41.5% | – | -303.6% | – | -253.0% | +4.3% | -37.2% | – | -298.6% | -65.3% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | -79.9% | -148.6% | +286.9% | +1,051.3% | -97.6% | +57.7% | -56.9% | +1,249.8% | – | -64.8% | -17.9% | +5.3% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | +0.0% | +0.0% | -180.0% | -75.0% | +0.0% | – | +150.0% | -49.2% | -100.0% | – | – | |
| – | +36.9% | +115.0% | +3.2% | +216.7% | -64.8% | -94.6% | +11.2% | +4.4% | -79.9% | +12,557.5% | +115.1% | +266.5% | -16.3% | -71.1% | +532.6% | -94.2% | +1,157.3% | +20.9% | +25.3% | -65.9% | -59.6% | +70.9% | -203.8% | |
| – | -55.4% | -137.9% | – | – | -120.3% | – | -162.7% | – | – | – | – | +1,147.7% | +380.3% | -88.0% | +3,450.9% | -149.6% | – | -139.8% | – | -85.6% | -215.7% | – | +348.8% | |
| – | – | – | – | – | – | -71.0% | -240.9% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -201.5% | – |
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.